Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$17.63 - $21.74 $55.3 Million - $68.2 Million
3,135,735 New
3,135,735 $61.9 Million
Q2 2023

Aug 14, 2023

SELL
$10.44 - $16.48 $3.33 Million - $5.26 Million
-319,350 Reduced 31.37%
698,741 $9.84 Million
Q1 2023

May 15, 2023

SELL
$10.7 - $15.79 $17.2 Million - $25.4 Million
-1,605,833 Reduced 61.2%
1,018,091 $11 Million
Q4 2022

Feb 14, 2023

SELL
$11.42 - $17.05 $3.38 Million - $5.05 Million
-296,099 Reduced 10.14%
2,623,924 $39.3 Million
Q3 2020

Nov 16, 2020

BUY
$15.21 - $25.53 $7.24 Million - $12.2 Million
476,190 Added 19.49%
2,920,023 $44.7 Million
Q2 2020

Aug 14, 2020

BUY
$15.08 - $26.0 $8.26 Million - $14.2 Million
547,945 Added 28.9%
2,443,833 $62.3 Million
Q4 2019

Feb 14, 2020

BUY
$5.24 - $12.96 $148,113 - $366,327
28,266 Added 1.51%
1,895,888 $21 Million
Q3 2019

Nov 14, 2019

BUY
$8.15 - $15.88 $258,632 - $503,935
31,734 Added 1.73%
1,867,622 $15.9 Million
Q1 2019

May 15, 2019

BUY
$15.93 - $26.59 $7.12 Million - $11.9 Million
447,000 Added 32.18%
1,835,888 $33.2 Million
Q4 2018

Feb 14, 2019

BUY
$16.25 - $28.09 $22.6 Million - $39 Million
1,388,888 New
1,388,888 $39 Million

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $687M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.